← back to search

Leiguang Ye

The First Affiliated Hospital, Sun Yat-sen University · CN
Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer research, Medicine, Lung cancer, Antibody, Biology, and Oncology.
h-index
citations
972
works
25
NIH funding
primary concept
email

Recent publications

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer
Signal Transduction and Targeted Therapy 2025cited by 5position: middledoi
Nanoengineered hydrogels disrupt tumor antioxidant defense via photothermal-chemodynamic synergy and oxidative stress boosts
Journal of Nanobiotechnology 2025cited by 2position: firstdoi
Targeting cancer stem-like cells via cholesterol modulation and ferroptosis induction using a multifunctional nanoplatform to overcome drug resistance
Journal of Nanobiotechnology 2025cited by 2position: firstdoi
VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation
The EMBO Journal 2024cited by 27position: middledoi
A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.
Journal of Clinical Oncology 2024cited by 4position: middledoi
Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor–Associated Pneumonitis in Patients With Lung Cancer
Journal of Immunotherapy 2024cited by 3position: middledoi
Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression
Cytokine & Growth Factor Reviews 2023cited by 47position: firstdoi
Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors
Thoracic Cancer 2023cited by 27position: middledoi
FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer
Breast Cancer Research and Treatment 2023cited by 26position: middledoi
Nucleus-exported CLOCK acetylates PRPS to promote de novo nucleotide synthesis and liver tumour growth
Nature Cell Biology 2023cited by 24position: middledoi
Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma
Thoracic Cancer 2023cited by 19position: middledoi
Correction: FN1-mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer
Breast Cancer Research and Treatment 2023cited by 3position: middledoi
Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer
Frontiers in Immunology 2022cited by 4position: lastdoi
MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway
Cellular Signalling 2020cited by 103position: lastdoi
SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis
Oncogene 2020cited by 32position: middledoi
MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug.
PubMed 2020cited by 29position: middle
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Cancer Cell 2019cited by 408position: middledoi
Influence of disease uncertainty to emotion among advanced lung cancer chemotherapy patients
˜The œJournal of practical nursing 2018cited by 0position: lastdoi
MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas
Oncology Reports 2015cited by 63position: middledoi
miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1
Tumor Biology 2015cited by 43position: firstdoi
Study of circulating IgG antibodies to BIRC5 and MYC in non‐small cell lung cancer
FEBS Open Bio 2015cited by 8position: firstdoi
Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma
Tumor Biology 2013cited by 26position: firstdoi
Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer
Tumor Biology 2013cited by 24position: middledoi
Circulating IgG antibody against FOXP3 may be a potential biomarker for lung cancer
Advances in Lung Cancer 2013cited by 4position: middledoi
Immunopontentiating and antitumor activities of a polysaccharide from Pulsatilla chinensis (Bunge) Regel
International Journal of Biological Macromolecules 2012cited by 39position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Baogang Liu · Sun Yat-sen University Cancer Center8 papers (2012–2024)Tong Liu · Beijing Tongren Hospital5 papers (2012–2023)Meisi Yan · Harbin Medical University5 papers (2019–2025) · 3 papers (2013–2013) · 3 papers (2013–2013)Fang� Yang · Wannan Medical College3 papers (2015–2024)Shilong Sun · Nanchang University3 papers (2013–2013)Weili Wang · Virginia Commonwealth University3 papers (2013–2015)Zhigao Li · Harbin Medical University3 papers (2020–2023)Jun Wei · Nanjing University of Chinese Medicine3 papers (2013–2013)Guimei Ji · Zhejiang University2 papers (2023–2024)Yingpu Li · Harbin Medical University2 papers (2022–2023)Ying‐Nai Wang · The University of Texas MD Anderson Cancer Center2 papers (2019–2025)Shen Yu-li · Zhejiang University2 papers (2023–2024)Heng‐Huan Lee · University of Houston2 papers (2019–2025)Mien‐Chie Hung · Institute of Biomedical Science2 papers (2019–2025)Hongfei Jiang · Guangxi University2 papers (2023–2024)Daqian Xu · Indiana University School of Medicine2 papers (2023–2024)Yuran Duan · Zhejiang University2 papers (2023–2024)Cong Zhang · Jilin University2 papers (2013–2013)